Inhibikase Therapeutics
IKT
IKT
31 hedge funds and large institutions have $163M invested in Inhibikase Therapeutics in 2024 Q4 according to their latest regulatory filings, with 23 funds opening new positions, 7 increasing their positions, 0 reducing their positions, and 3 closing their positions.
Holders
31
Holders Change
+20
Holders Change %
+181.82%
% of All Funds
0.41%
Holding in Top 10
2
Holding in Top 10 Change
+2
Holding in Top 10 Change %
%
% of All Funds
0.03%
New
23
Increased
7
Reduced
–
Closed
3
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–
Top Buyers
Top Sellers
| 1 |
AC
1
Armistice Capital
New York
|
$0 |
| 2 |
2
Renaissance Technologies
New York
|
$0 |
| 3 |
TRCT
3
Tower Research Capital (TRC)
New York
|
$0 |
| Name | Holding | Trade Value |
Shares Change |
Shares Change % |
|
|---|---|---|---|---|---|
|
JFG
26
Jefferies Financial Group
New York
| $48.1K | +$48.1K | +14,800 | New |
|
27
Stifel Financial
St. Louis,
Missouri
| $42.7K | +$42.7K | +13,129 | New |
|
28
Morgan Stanley
New York
| $23.7K | +$18.3K | +5,629 | +338% |
|
29
Bank of America
Charlotte,
North Carolina
| $14.7K | +$14.5K | +4,456 | +8,408% |
|
30
Wells Fargo
San Francisco,
California
| $543 | – | – | – |
|
|
SAM
31
Synergy Asset Management
Vancouver,
Washington
| $65 | +$65 | +50 | New |
|
|
AC
32
Armistice Capital
New York
| – | -$814K | -626,500 | Closed |
|
|
33
Renaissance Technologies
New York
| – | -$25.9K | -19,922 | Closed |
|
|
TRCT
34
Tower Research Capital (TRC)
New York
| – | -$5.27K | -4,057 | Closed |
|